NEORNAT

NEORNAT Inc. is a first-in-class drug development company that fundamentally redefines the pathophysiology of cancer and inflammatory and fibrotic diseases based on its proprietary RNA platform. Leveraging our RNA-based core technology that precisely controls immune imbalance in the disease microenvironment, we aim to overcome the limitations of existing therapies and present a new therapeutic paradigm. In particular, we are securing global competitiveness through the development of innovative therapeutics utilizing macrophage reprogramming mechanisms. Our key pipeline, NRT-YHD, is being advanced as a next-generation RNA immuno-oncology therapy in global clinical development. Along with NRT-FX, which is expanded into metabolic and fibrotic disease treatments, we are implementing a multi-indication therapeutic strategy based on a single platform.